COMPANY PROFILE

HoneyNaps

Explore full profile

Bio signal management platform enhancing disease prediction and monitoring through advanced sleep analysis technology

Seoul, South KoreaFounded 2015Health

Valuation $50–100M Last recorded · 2024

Total funding $10–50M Disclosed equity funding

Unlock exact values

About HoneyNaps

HoneyNaps operates in the digital healthcare sector, focusing on developing technologies for disease diagnosis, bio signal monitoring, and treatment assessments. The company serves medical professionals and researchers by providing a platform that facilitates disease prediction and bio signal management. HoneyNaps' core product, SOMNUM, is a breakthrough platform technology designed to collect and analyze bio signals, such as body temperature, heart rate, and movement during sleep, to detect abnormal symptoms early. The business model revolves around offering a shared platform that integrates these technologies into clinical practice, aiming to make healthcare more accessible and personalized. HoneyNaps generates revenue by licensing its platform and technologies to healthcare providers and researchers, contributing to the advancement of 4P Medicine—Prevention, Prediction, Participation, and Personalization. The company is committed to improving global health outcomes by leveraging its expertise in bio signal analysis and disease prediction algorithms.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Seoul, South Korea
Open positions: None listed
Dealroom signal: 20.0/100
Industry: Health
Sector: Health, Health Diagnostics, Sleeping
Technology: Artificial Intelligence
Business model: SaaS
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	May 2024	$12M	$46M	Industrial Bank of Korea · QUAD Investment Management · Hi Investment Partners	↗
SERIES AEquity / VC	Jan 2021	$3.9M	$16M	Undisclosed	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

HoneyNaps website traffic

Latest recorded traffic for HoneyNaps is 1.7K monthly website visits, up 431.3% over the last three months.

Latest monthly visits1.7K 3-month web change+431.3%

Monthly website visitsOct 2023–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioSerenityLeading global providers of remote diagnostic solutions	Paris, France	Operational	272	$118M	$358M
CECentAI-powered early detection for serious diseases.	Bengaluru, India	Operational
JAjaidePlatform matching families with verified caregivers for childcare, eldercare, and disability support using screening and AI-based tools	Paris, France	Operational
TATagomicsMultiomic platform for disease biomarker discovery and diagnostics	Cambridge, United Kingdom	Operational
NHNeu HealthSmartphone platform for Parkinson's and dementia care	London, United Kingdom	Operational
RARaidiumRaidium foundation model: Radiology augmented GPT to tackle the complexity of precision medicine	Roubaix, France	Operational
MAmachineMDRadically improving the early diagnosis of brain disorders	Bern, Switzerland	Operational
AIAiosynDeveloping, integrating, and certifying AI solutions for clinical diagnostic support for complex diseases such as prostate and breast cancer	Nijmegen, Netherlands	Operational